NOVUSPHARMA_(UK)_LTD - Accounts

Company registration number 12461049 (England and Wales)
NOVUSPHARMA (UK) LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023
PAGES FOR FILING WITH REGISTRAR
NOVUSPHARMA (UK) LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
NOVUSPHARMA (UK) LTD
BALANCE SHEET
AS AT
30 JUNE 2023
30 June 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Intangible assets
3
3,689,147
3,003,244
Tangible assets
4
186,829
114,523
3,875,976
3,117,767
Current assets
Stocks
628,335
404,649
Debtors
5
1,095,988
667,743
Cash at bank and in hand
478,152
572,707
2,202,475
1,645,099
Creditors: amounts falling due within one year
6
(3,423,611)
(2,142,712)
Net current liabilities
(1,221,136)
(497,613)
Total assets less current liabilities
2,654,840
2,620,154
Creditors: amounts falling due after more than one year
7
(2,053,073)
(2,099,636)
Provisions for liabilities
(38,292)
(21,759)
Net assets
563,475
498,759
Capital and reserves
Called up share capital
10,000
10,000
Profit and loss reserves
553,475
488,759
Total equity
563,475
498,759

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

NOVUSPHARMA (UK) LTD
BALANCE SHEET (CONTINUED)
AS AT
30 JUNE 2023
30 June 2023
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 15 March 2024 and are signed on its behalf by:
Mr KK Patel
Director
Company registration number 12461049 (England and Wales)
NOVUSPHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023
- 3 -
1
Accounting policies
Company information

Novuspharma (UK) Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, HA5 5QA.

1.1
Reporting period

The Company changed its previous accounting period from 30 September 2022 to 30 June 2022 to align its year end with other companies controlled by common directors. The prior period financial statements were prepared for a period of nine months hence the comparative amounts presented in the financial statements (included the related notes) are not entirely comparable.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is fifteen years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

NOVUSPHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Straight line over 15 years
Plant and equipment
25% on reducing balance
Fixtures and fittings
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

NOVUSPHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
1
Accounting policies
(Continued)
- 5 -
1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Leases

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

1.12
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
62
59
NOVUSPHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
- 6 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 July 2022
3,361,227
Additions
938,246
At 30 June 2023
4,299,473
Amortisation and impairment
At 1 July 2022
357,983
Amortisation charged for the year
252,343
At 30 June 2023
610,326
Carrying amount
At 30 June 2023
3,689,147
At 30 June 2022
3,003,244
4
Tangible fixed assets
Leasehold land and buildings
Plant and equipment
Fixtures and fittings
Total
£
£
£
£
Cost
At 1 July 2022
12,501
5,000
156,795
174,296
Additions
19,257
-
0
84,171
103,428
At 30 June 2023
31,758
5,000
240,966
277,724
Depreciation and impairment
At 1 July 2022
513
1,674
57,586
59,773
Depreciation charged in the year
1,279
832
29,011
31,122
At 30 June 2023
1,792
2,506
86,597
90,895
Carrying amount
At 30 June 2023
29,966
2,494
154,369
186,829
At 30 June 2022
11,988
3,326
99,209
114,523
NOVUSPHARMA (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2023
- 7 -
5
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
793,259
538,642
Other debtors
302,729
129,101
1,095,988
667,743
6
Creditors: amounts falling due within one year
2023
2022
£
£
Bank loans
87,588
128,613
Trade creditors
2,593,631
1,656,823
Taxation and social security
94,352
74,582
Other creditors
648,040
282,694
3,423,611
2,142,712
7
Creditors: amounts falling due after more than one year
2023
2022
Notes
£
£
Bank loans and overdrafts
2,053,073
2,099,636

Bank loans payable within and after one year are secured by way of a fixed and floating charge over all the assets of the company.

Amounts included above which fall due after five years are as follows:
Payable by instalments
1,702,721
1,790,309
8
Related party transactions

Included within the other creditors is £579,723 payable to entities with some common shareholders and directors. The outstanding balance is unsecured, interest free and repayable on demand.

Included within the trade creditors is £1,775,894 payable to entities with some common shareholders and directors. The outstanding balance is unsecured, interest free and repayable on demand.

 

2023-06-302022-07-01false15 March 2024CCH SoftwareCCH Accounts Production 2023.300No description of principal activityMr KK PatelMr ASK Patelfalse124610492022-07-012023-06-30124610492023-06-30124610492022-06-3012461049core:NetGoodwill2023-06-3012461049core:NetGoodwill2022-06-3012461049core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-06-3012461049core:PlantMachinery2023-06-3012461049core:FurnitureFittings2023-06-3012461049core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-06-3012461049core:PlantMachinery2022-06-3012461049core:FurnitureFittings2022-06-3012461049core:CurrentFinancialInstrumentscore:WithinOneYear2023-06-3012461049core:CurrentFinancialInstrumentscore:WithinOneYear2022-06-3012461049core:Non-currentFinancialInstrumentscore:AfterOneYear2023-06-3012461049core:Non-currentFinancialInstrumentscore:AfterOneYear2022-06-3012461049core:CurrentFinancialInstruments2023-06-3012461049core:CurrentFinancialInstruments2022-06-3012461049core:ShareCapital2023-06-3012461049core:ShareCapital2022-06-3012461049core:RetainedEarningsAccumulatedLosses2023-06-3012461049core:RetainedEarningsAccumulatedLosses2022-06-3012461049bus:Director12022-07-012023-06-3012461049core:Goodwill2022-07-012023-06-3012461049core:LandBuildingscore:LongLeaseholdAssets2022-07-012023-06-3012461049core:PlantMachinery2022-07-012023-06-3012461049core:FurnitureFittings2022-07-012023-06-30124610492021-10-012022-06-3012461049core:NetGoodwill2022-06-3012461049core:NetGoodwill2022-07-012023-06-3012461049core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-06-3012461049core:PlantMachinery2022-06-3012461049core:FurnitureFittings2022-06-30124610492022-06-3012461049core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-07-012023-06-3012461049core:WithinOneYear2023-06-3012461049core:WithinOneYear2022-06-3012461049core:Non-currentFinancialInstruments2023-06-3012461049core:Non-currentFinancialInstruments2022-06-3012461049bus:PrivateLimitedCompanyLtd2022-07-012023-06-3012461049bus:SmallCompaniesRegimeForAccounts2022-07-012023-06-3012461049bus:FRS1022022-07-012023-06-3012461049bus:AuditExemptWithAccountantsReport2022-07-012023-06-3012461049bus:Director22022-07-012023-06-3012461049bus:FullAccounts2022-07-012023-06-30xbrli:purexbrli:sharesiso4217:GBP